Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Novocure Ltd before investing.

In this article, we go over a few key elements for understanding Novocure Ltd’s stock price such as:

• Novocure Ltd’s current stock price and volume
• Why Novocure Ltd’s stock price changed recently
• Upgrades and downgrades for NVCR from analysts
• NVCR’s stock price momentum as measured by its relative strength

About Novocure Ltd (NVCR)

Before we jump into Novocure Ltd’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Want to learn more about Novocure Ltd’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Novocure Ltd.

Novocure Ltd’s Stock Price as of Market Close

As of June 04, 2024, 4:00 PM, CST, Novocure Ltd’s stock price was $22.82.

Novocure Ltd is down 4.48% from its previous closing price of $23.89.

During the last market session, Novocure Ltd’s stock traded between $22.42 and $24.04. Currently, there are 107.27 million shares of Novocure Ltd stock available for purchase.

Unfortunately, Novocure Ltd’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Novocure Ltd Stock Price History

Novocure Ltd’s (NVCR) price is currently up 3.68% so far this month.

During the month of June, Novocure Ltd’s stock price has reached a high of $24.40 and a low of $22.42.

Over the last year, Novocure Ltd has hit prices as high as $82.64 and as low as $10.87. Year to date, Novocure Ltd’s stock is down 68.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Novocure Ltd Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 03, 2024, there were 0 analysts who downgraded Novocure Ltd’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Novocure Ltd’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Novocure Ltd’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Novocure Ltd’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Novocure Ltd (NVCR) by visiting AAII Stock Evaluator.

Relative Price Strength of Novocure Ltd

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 03, 2024, Novocure Ltd has a weighted four-quarter relative price strength of -3.72%, which translates to a Momentum Score of 52 and is considered to be Average.

Want to learn more about how Novocure Ltd is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Novocure Ltd Stock Price: Bottom Line

As of June 4, 2024, Novocure Ltd’s stock price is $22.82, which is down 4.48% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Novocure Ltd stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.